WO2015060650A3 - 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물 - Google Patents

간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물 Download PDF

Info

Publication number
WO2015060650A3
WO2015060650A3 PCT/KR2014/009971 KR2014009971W WO2015060650A3 WO 2015060650 A3 WO2015060650 A3 WO 2015060650A3 KR 2014009971 W KR2014009971 W KR 2014009971W WO 2015060650 A3 WO2015060650 A3 WO 2015060650A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
isoforms
lateral sclerosis
amyotrophic lateral
preventing
Prior art date
Application number
PCT/KR2014/009971
Other languages
English (en)
French (fr)
Other versions
WO2015060650A2 (ko
Inventor
정재균
Original Assignee
주식회사 바이로메드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201480058075.3A priority Critical patent/CN105682676B/zh
Priority to US15/030,999 priority patent/US10639351B2/en
Priority to MX2016005006A priority patent/MX2016005006A/es
Priority to EP14856385.1A priority patent/EP3061457B1/en
Application filed by 주식회사 바이로메드 filed Critical 주식회사 바이로메드
Priority to CA2926607A priority patent/CA2926607C/en
Priority to RU2016119116A priority patent/RU2639582C2/ru
Priority to JP2016546724A priority patent/JP6240337B2/ja
Priority to ES14856385T priority patent/ES2773305T3/es
Priority to AU2014337870A priority patent/AU2014337870B2/en
Priority to SG11201602452SA priority patent/SG11201602452SA/en
Priority to BR112016008267A priority patent/BR112016008267A2/pt
Priority claimed from KR1020140143377A external-priority patent/KR101779775B1/ko
Publication of WO2015060650A2 publication Critical patent/WO2015060650A2/ko
Publication of WO2015060650A3 publication Critical patent/WO2015060650A3/ko
Priority to HK16107864.0A priority patent/HK1219873A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 HGF(Hepatocyte Growth Factor)의 둘 이상의 이형체들 또는 상기 이형체들을 암호화하는 폴리뉴클레오타이드를 유효성분으로 포함하는 근위축성 측삭 경화증(Amyotrophic Lateral Sclerosis) 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명의 조성물을 사용함으로써 근위축성 측삭 경화증(Amyotrophic Lateral Sclerosis)을 효과적으로 예방 또는 치료할 수 있다.
PCT/KR2014/009971 2013-10-22 2014-10-22 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물 WO2015060650A2 (ko)

Priority Applications (12)

Application Number Priority Date Filing Date Title
RU2016119116A RU2639582C2 (ru) 2013-10-22 2014-10-22 Композиция для предупреждения или лечения бокового амиотрофического склероза с использованием двух или более изоформ фактора роста гепатоцитов
MX2016005006A MX2016005006A (es) 2013-10-22 2014-10-22 Composicion para prevenir a tratar la esclerosis lateral amiotrofica usando dos o mas isoformas del factor de crecimiento de hepatocito.
EP14856385.1A EP3061457B1 (en) 2013-10-22 2014-10-22 Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor
ES14856385T ES2773305T3 (es) 2013-10-22 2014-10-22 Composición para la prevención o tratamiento de la esclerosis lateral amiotrófica que utiliza dos o más isoformas del factor de crecimiento de hepatocitos
CA2926607A CA2926607C (en) 2013-10-22 2014-10-22 Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor
US15/030,999 US10639351B2 (en) 2013-10-22 2014-10-22 Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor
JP2016546724A JP6240337B2 (ja) 2013-10-22 2014-10-22 肝細胞増殖因子の２つ以上のアイソフォームを利用した筋萎縮性側索硬化症の予防又は治療用組成物
CN201480058075.3A CN105682676B (zh) 2013-10-22 2014-10-22 利用肝细胞生长因子的两种以上的异构体的肌萎缩性侧索硬化症预防或治疗用组合物
AU2014337870A AU2014337870B2 (en) 2013-10-22 2014-10-22 Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor
SG11201602452SA SG11201602452SA (en) 2013-10-22 2014-10-22 Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor
BR112016008267A BR112016008267A2 (pt) 2013-10-22 2014-10-22 Composição para prevenir ou tratar esclerose lateral amiotrófica usando duas ou mais isoformas de fator de crescimento de hepatócito
HK16107864.0A HK1219873A1 (zh) 2013-10-22 2016-07-06 利用肝細胞生長因子的兩種以上的異構體的肌萎縮性側索硬化症預防或治療用組合物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20130126216 2013-10-22
KR10-2013-0126216 2013-10-22
KR10-2014-0143377 2014-10-22
KR1020140143377A KR101779775B1 (ko) 2013-10-22 2014-10-22 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물

Publications (2)

Publication Number Publication Date
WO2015060650A2 WO2015060650A2 (ko) 2015-04-30
WO2015060650A3 true WO2015060650A3 (ko) 2015-06-11

Family

ID=52993719

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2014/009971 WO2015060650A2 (ko) 2013-10-22 2014-10-22 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물

Country Status (1)

Country Link
WO (1) WO2015060650A2 (ko)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
KR20000046969A (ko) 1998-12-31 2000-07-25 이선경 이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HENRIQUES, A. ET AL.: "Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?''.", FRONTIERS IN NEUROSCIENCE, vol. 4, no. 32, 2010, pages 1 - 14, XP055340121 *
KADOYAMA, K. ET AL.: "Hepatocyte growth factor (HGF) attenuates gliosis and motoneuronal degeneration in the brainstem motor nuclei of a transgenic mouse model of ALS''.", NEUROSCIENCE RESEARCH, vol. 59, 2007, pages 446 - 456, XP022321346 *
WARITA, H. ET AL.: "Clinical translation of hepatocyte growth factor for amyotrophic lateral sclerosis''.", RINSHO SHINKEIGAKU, vol. 52, 2012, pages 1214 - 1217, XP055340118 *

Also Published As

Publication number Publication date
WO2015060650A2 (ko) 2015-04-30

Similar Documents

Publication Publication Date Title
PH12017501921A1 (en) Novel compounds
PH12017501079A1 (en) 1,3-thiazol-2-yl substituted benzamides
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MX2018005829A (es) Composiciones para tratar el cabello.
JO3452B1 (ar) بنزاميدات أمينو اريل مغاير كمثبطات كيناز
MX370032B (es) Agonistas del receptor de esfingosina-1-fosfato, metodos para prepararlos y composiciones farmaceuticas que contienen los mismos como un agente activo.
MX2016007898A (es) Compuestos diaminopirimidilo sustituidos, las composiciones de estos y los metodos de tratamiento con estos.
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
PH12016501807A1 (en) Novel compounds
WO2014113429A3 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MX2018005418A (es) Sililfenoxiheterociclos trisustituidos y analogos.
NZ702087A (en) Pharmaceutical compositions and treatment of mastitis
PH12017501133A1 (en) Pyrazolopyridinamines
PH12016500054A1 (en) Substituted pyrazolo-pyridinamines
MY180006A (en) Azetidinyloxyphenylpyrrolidine compounds
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
MX2016005006A (es) Composicion para prevenir a tratar la esclerosis lateral amiotrofica usando dos o mas isoformas del factor de crecimiento de hepatocito.
EP2910247A4 (en) COMPOSITIONS FOR PREVENTING OR TREATING ALLERGIC SKIN DISORDERS CONTAINING GPCR19 AGENTS AS ACTIVE INGREDIENTS
WO2015144652A3 (en) Heterocyclic compounds for the control of unwanted microorganisms
EP3061448A4 (en) Composition containing eugenol as active ingredient for preventing or treating atopic dermatitis
WO2015152577A3 (ko) 골 질환 예방 및 치료용 조성물
EP3037091A4 (en) Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma
EP3042651A4 (en) Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating atopic dermatitis
EP3006434A4 (en) Novel compound derived from plant of genus quamoclit and composition containing same as active ingredient for preventing or treating diabetes
EP2594268A4 (en) ANGIOGENIC INHIBITORY COMPOSITION WITH MACROLACTIN A AND A DERIVATIVELY AS ACTIVE SUBSTANCES

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14856385

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2926607

Country of ref document: CA

Ref document number: 2016546724

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/005006

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 15030999

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016008267

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2014337870

Country of ref document: AU

Date of ref document: 20141022

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2014856385

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014856385

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016119116

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112016008267

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160414